

Change in composite summary SUVR-MCG
Improvement
0.10
0.05
0.00
-0.05
-0.10
-0.15
-0.20
0
10
26
52
76
100
152
Week
Dose Group:
Placebo
ACI-24 100 ug
ACI-24 300 ug
ACI-24 1000 ug
End of treatment period:
Cohorts 1-3
Cohort 4

Figure 1



Change in MMSE total score
Improvement
5
0
-5
-10
-15
Week
0
10
26
52
76
100
152
End of treatment period:
Cohorts 1-3
Cohort 4
Dose Group:
ACI-24 10 ug
ACI-24 300 ug
Placebo
Placebo (C4 schedule)
ACI-24 100 ug
ACI-24 1000 ug
ACI-24 1000 ug (C4 schedule)

Figure 2



Change in CDR-SB score
Improvement
10
8
6
4
2
0
-2
End of treatment period:
Cohorts 1-3
Cohort 4
0
10
26
52
76
100
152
Week
Dose Group:
ACI-24 10 ug
ACI-24 100 ug
ACI-24 300 ug
ACI-24 1000 ug
Placebo
ACI-24 1000 ug (C4 schedule)
Placebo (C4 schedule)

Figure 3